文献速递神经肿瘤

帕比司他治疗成人H3 K27M突变型弥漫性中线胶质瘤:单中心经验

Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience.
PubMed 文献 · J Neurooncol · 2022-01-25

该单中心回顾性研究报告了2016年1月至2020年8月在Mayo Clinic(Rochester)接受帕比司他治疗的4例成人H3 K27M突变型弥漫性中线胶质瘤患者,中位年龄40岁,2例女性,肿瘤位于脊髓2例、脑干1例、丘脑1例。所有患者均未出现CTCAE 2级或以上不良事件,中位总生存期42个月,中位无进展生存期19个月,末次随访时2例存活。

要点

  • 帕比司他在所描述的剂量方案下耐受良好,研究期间无严重不良事件。
  • 4例成人H3 K27M突变型DMG患者中位OS 42个月,中位PFS 19个月。
  • 末次随访时2例存活,均为脊髓肿瘤且接受过放疗。

核心结论

  • 这是首份关于帕比司他治疗成人H3 K27M突变型弥漫性中线胶质瘤临床结局的报告。
  • 作者显示帕比司他在其所描述的剂量方案下耐受良好,研究期间无严重不良事件。

研究设计与样本

  • 单中心回顾性研究,纳入2016年1月至2020年8月在Mayo Clinic(Rochester)接受帕比司他治疗的成人(>18岁)H3 K27M突变型弥漫性中线胶质瘤患者,随访至2021年10月。
  • 共4例患者接受帕比司他作为同情用药,中位年龄40岁(范围22-62岁),2例女性。
  • 肿瘤位置均为中线,其中脊髓2例、脑干1例、丘脑1例;所有肿瘤均为IDH1/IDH2野生型。
  • 3例患者接受放疗后序贯帕比司他辅助治疗;除3例同时使用地塞米松外,所有患者在帕比司他治疗前或治疗期间均未使用其他药物治疗。
  • 生存分析采用Kaplan-Meier法。

主要发现

  • 无患者出现CTCAE 2级或以上不良事件。
  • 中位总生存期为42个月,中位无进展生存期为19个月。
  • 末次随访时2例患者存活,均为脊髓肿瘤且接受过放疗。
  • 最佳疗效为2例疾病稳定、1例部分缓解。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Diffuse midline gliomas (DMG) with the H3 K27M-mutation are a well-described entity with most DMG harboring this mutation, with notable heterogeneity in adults. No therapy has been proven to improve survival in this tumor type. Panobinostat is a histone deacetylase inhibitor that may have therapeutic benefit. METHODS: We report our retrospective experience with use of panobinostat in adults (> 18 years) with H3 K27M-mutant DMG treated at Mayo Clinic (Rochester) from January 2016 to August 2020, with follow-up until October 2021. Survival was calculated using the Kaplan-Meier method. RESULTS: 4 patients with H3 K27M-mutant glioma were treated with panobinostat as compassionate use. Patients had a median age of 40 years (range 22-62 years) and 2 were female. Tumor location was midline for all patients, spinal cord (n = 2), brainstem (n = 1), and thalamus (n = 1). All tumors were IDH1/IDH2 wildtype. 3 patients received radiotherapy followed by adjuvant panobinostat. All patients had no other pharmacologic therapy utilized prior to or during panobinostat therapy aside from concurrent dexamethasone utilized in 3 patients. No patient experienced a grade 2 or higher (per CTCAE grade) adverse effect. The median overall survival was 42 months, median progression free survival of 19 months, 2 patients were alive at last follow up (both with spinal cord tumors and received radiation). The best response was stable disease in 2 patients and a partial response in 1 patient. CONCLUSIONS: This is the first report of clinical outcomes of panobinostat in adults with H3 K27M-mutant DMG. We showed that it is well-tolerated at the dosage schedule that we describe, with no serious adverse effects throughout the study period.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Neth BJ, Balakrishnan SN, Carabenciov ID, et al. Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience. J Neurooncol. 2022. PMID: 35076860. doi:10.1007/s11060-022-03950-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。